Department of Surgery, Austin Hospital and University of Melbourne, Melbourne, Victoria, Australia.
Department of Surgery, Austin Hospital and University of Melbourne, Melbourne, Victoria, Australia.
Hepatobiliary Pancreat Dis Int. 2017 Oct 15;16(5):458-469. doi: 10.1016/S1499-3872(17)60055-9.
Fluid intervention and vasoactive pharmacological support during hepatic resection depend on the preference of the attending clinician, institutional resources, and practice culture. Evidence-based recommendations to guide perioperative fluid management are currently limited. Therefore, we provide a contemporary clinical integrative overview of the fundamental principles underpinning fluid intervention and hemodynamic optimization for adult patients undergoing major hepatic resection.
A literature review was performed of MEDLINE, EMBASE and the Cochrane Central Registry of Controlled Trials using the terms "surgery", "anesthesia", "starch", "hydroxyethyl starch derivatives", "albumin", "gelatin", "liver resection", "hepatic resection", "fluids", "fluid therapy", "crystalloid", "colloid", "saline", "plasma-Lyte", "plasmalyte", "hartmann's", "acetate", and "lactate". Search results for MEDLINE and EMBASE were additionally limited to studies on human populations that included adult age groups and publications in English.
A total of 113 articles were included after appropriate inclusion criteria screening. Perioperative fluid management as it relates to various anesthetic and surgical techniques is discussed.
Clinicians should have a fundamental understanding of the surgical phases of the resection, hemodynamic goals, and anesthesia challenges in attempts to individualize therapy to the patient's underlying pathophysiological condition. Therefore, an ideal approach for perioperative fluid therapy is always individualized. Planning and designing large-scale clinical trials are imperative to define the optimal type and amount of fluid for patients undergoing major hepatic resection. Further clinical trials evaluating different intraoperative goal-directed strategies are also eagerly awaited.
肝切除术中的液体干预和血管活性药物支持取决于主治临床医生的偏好、机构资源和实践文化。目前,指导围手术期液体管理的循证建议有限。因此,我们提供了一个当代临床综合概述,阐述了成人行大肝切除术中液体干预和血流动力学优化的基本原则。
使用“手术”、“麻醉”、“淀粉”、“羟乙基淀粉衍生物”、“白蛋白”、“明胶”、“肝切除术”、“肝切除术”、“液体”、“液体疗法”、“晶体液”、“胶体液”、“盐水”、“Plasma-Lyte”、“Plasmalyte”、“Hartmann's”、“醋酸盐”和“乳酸盐”等术语,对 MEDLINE、EMBASE 和 Cochrane 对照试验中心注册库进行了文献回顾。对 MEDLINE 和 EMBASE 的搜索结果还另外限制在包括成年年龄组的人类人群研究和英文出版物中。
经过适当的纳入标准筛选,共纳入 113 篇文章。讨论了与各种麻醉和手术技术相关的围手术期液体管理。
临床医生应基本了解切除的手术阶段、血流动力学目标和麻醉挑战,以尝试根据患者的潜在病理生理状况对治疗进行个体化。因此,围手术期液体治疗的理想方法始终是个体化的。规划和设计大规模临床试验对于确定行大肝切除术患者的最佳液体类型和数量至关重要。还急切期待评估不同术中目标导向策略的进一步临床试验。